A systematic review examines the cellular mechanisms, pharmacokinetic limitations, and available clinical evidence for the ...

Fat fraction, together with clinical endpoints, may support a potential accelerated approval pathway for forazapadin Protocol ...

Attovia Therapeutics (NASDAQ:ATTO) reported 12-week results from a small phase 1b study of its experimental itch treatment ...

Zydus Therapeutics, a subsidiary of Zydus Lifesciences Limited, has announced encouraging results from its Phase 2b clinical ...

Meaningful antitumor activity observed at the 3.0 mCi monotherapy dose with 75% disease control rate and durable disease stabilization; one of two confirmed responders remains on study ~40 weeks after ...

In this video interview, James Cheong, senior vice president of Asia Pacific at Precision for Medicine, explains how FDA ...

InnoCare’s orelabrutinib posts 32.8% durable platelet response in Phase III ITP, topping Sanofi’s rilzabrutinib. NMPA NDA ...

(Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo ...

First patient dosed in Phase 2 Vista PD study evaluating VIM0423,a potential first-in-class daily oral therapeutic, for the treatment of refractory tremor in adults with Parkinson’s disease ...

CytomX Therapeutics earns a Buy rating on strong Varseta-M colorectal cancer data, cash runway, and upside potential. Learn ...

BHP steel decarbonisation trials cover a quarter of global output. See the NeoSmelt FID timeline, blast furnace results and ...

Genetox, a latecomer in the botulinum toxin market, has completed the administration and follow-up observation of subjects in ...